In a groundbreaking application of data science, researchers have revisited the landmark Diabetes Control and Complications Trial (DCCT) by integrating virtual continuous glucose monitoring (CGM) traces into the original study data. This innovative approach aims to assess the association between CGM-derived time-in-range (TIR) metrics and the risk of microvascular complications in individuals with Type 1 diabetes (T1D), potentially establishing TIR as a reliable marker of glycaemic control and paving the way for more personalised disease management.

Type 1 diabetes is a chronic condition characterised by the body’s inability to produce insulin, necessitating lifelong insulin therapy. Effective management is crucial to prevent complications such as cardiovascular disease, neuropathy and kidney damage. The DCCT, conducted from 1983 to 1993, demonstrated that intensive insulin therapy reduces the risk of microvascular complications compared to conventional therapy. However, the study relied primarily on glycated haemoglobin (HbA1c) and sparse blood glucose measurements, providing limited insight into daily glucose fluctuations. The integration of virtual CGM traces addresses this gap by offering a more comprehensive view of glucose variability and its impact on long-term health outcomes, positioning TIR as a dynamic and actionable metric for guiding treatment decisions.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Using a multistep machine-learning process, researchers synthesised CGM data from DCCT participants by leveraging existing blood glucose (BG) profiles and HbA1c measurements. This process involved modeling BG variability, associating individual profiles with archival BG traces and applying previously identified CGM “motifs” to estimate daily glucose patterns. The results revealed that the intensive therapy group achieved a TIR greater than 60%, whereas the conventional therapy group maintained TIR below 40%. More importantly, TIR was significantly associated with the risk of retinopathy, nephropathy and neuropathy, similar to the predictive value of HbA1c, with all associations showing statistical significance (P-values <0.0001). These findings suggest that TIR could complement or even replace HbA1c as a primary indicator of diabetes control, enabling more timely interventions.

A dynamic and actionable metric for treatment decisions

Key opinion leaders (KOLs) continue to advocate for the broader adoption of CGM technology in diabetes care. An American KOL recently emphasised: “We really encourage technology. Using CGM at the time of diagnosis makes a world of difference.” This study reinforces the value of CGM-derived metrics, such as TIR, as actionable indicators for optimising diabetes management and reducing complications. By revisiting historical data with modern analytical techniques, this research underscores the evolving role of technology in shaping diabetes care and highlights how TIR may drive a shift towards more individualised treatment approaches.

Despite these promising findings, challenges remain in translating virtual CGM data into clinical practice. The competitive landscape of diabetes management includes established CGM and insulin delivery technologies from companies such as DexCom, Abbott and Medtronic. However, the ability to retrospectively analyse landmark trials with contemporary tools offers a compelling opportunity to refine treatment guidelines and drive further innovation. As healthcare systems increasingly embrace digital health solutions, incorporating CGM-derived insights may enhance personalised treatment strategies and improve patient adherence, potentially shifting the focus from reactive to proactive diabetes management.

The integration of virtual CGM data into the DCCT represents a significant advancement in diabetes research. By demonstrating that 14-day CGM metrics can predict microvascular complications similarly to HbA1c, this study highlights the potential for CGM technology to become a cornerstone in modern diabetes management. Moving forward, further research and real-world validation of CGM-derived insights will be critical to fully harness the potential of this approach, enhancing clinical decision-making and improving patient outcomes.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

This study reinforces the significance of intensive glycaemic control and presents a paradigm shift in managing T1D and its complications. The findings suggest that TIR could become a more dynamic and actionable metric compared to traditional HbA1c measurements, offering patients and healthcare providers real-time insights for proactive intervention. This could lead to a more individualised approach to diabetes care, where treatment adjustments are based on short-term glucose patterns rather than long-term averages. Moreover, the use of machine learning to analyse historical trial data underscores the potential of data-driven healthcare to refine clinical guidelines and support precision medicine in diabetes management.